Shortened Up-Dosing With 7 Injections of Subcutaneous Allergy Immunotherapy (Alutard SQ) Is Safe and Well Tolerated

Horn et al discuss their partly randomized, parallel-group, controlled (open-label), multicenter trial to compare the safety and tolerability profile of a 7-injection up-dosing schedule with the registered and widely used Allergy immunotherapy (AIT) product Alutard SQ (ALK, based on either 6 grasses and rye, birch, or HDM allergens) with that of the established 11-injection up-dosing schedule for grass pollen allergens. The trial was conducted in Germany and Spain from 2017 to 2018. Allergic rhinoconjunctivitis is caused mainly by allergens from grass pollen, Fagales tree pollen, and house dust mites. AIT can be applied by the subcutaneous or sublingual route and is the only treatment of ARC with the potential for long-term effect and disease modification.